Treatment of the antiphospholipid antibody syndrome

progress in the last five years?

Research output: Contribution to journalArticle

Abstract

The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains high-intensity warfarin, and, in pregnancy, heparin and aspirin. Exciting developments include the potential role of hydroxychloroquine as a prophylactic drug, stem cell transplantation, and B-cell tolerance. Animal models appear to be a fruitful "proving ground" of new therapies. The introduction of revised classification criteria for APS should aid in appropriate characterization of, and selection of, patients for clinical trials.

Original languageEnglish (US)
Pages (from-to)256-261
Number of pages6
JournalCurrent Rheumatology Reports
Volume2
Issue number3
StatePublished - Jun 2000

Fingerprint

Antiphospholipid Syndrome
Hydroxychloroquine
Stem Cell Transplantation
Warfarin
Patient Selection
Aspirin
Heparin
Thrombosis
B-Lymphocytes
Animal Models
Clinical Trials
Pregnancy
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Rheumatology

Cite this

Treatment of the antiphospholipid antibody syndrome : progress in the last five years? / Petri, Michelle.

In: Current Rheumatology Reports, Vol. 2, No. 3, 06.2000, p. 256-261.

Research output: Contribution to journalArticle

@article{97ca6c0406ef4119923bb7792a0a9287,
title = "Treatment of the antiphospholipid antibody syndrome: progress in the last five years?",
abstract = "The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains high-intensity warfarin, and, in pregnancy, heparin and aspirin. Exciting developments include the potential role of hydroxychloroquine as a prophylactic drug, stem cell transplantation, and B-cell tolerance. Animal models appear to be a fruitful {"}proving ground{"} of new therapies. The introduction of revised classification criteria for APS should aid in appropriate characterization of, and selection of, patients for clinical trials.",
author = "Michelle Petri",
year = "2000",
month = "6",
language = "English (US)",
volume = "2",
pages = "256--261",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Treatment of the antiphospholipid antibody syndrome

T2 - progress in the last five years?

AU - Petri, Michelle

PY - 2000/6

Y1 - 2000/6

N2 - The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains high-intensity warfarin, and, in pregnancy, heparin and aspirin. Exciting developments include the potential role of hydroxychloroquine as a prophylactic drug, stem cell transplantation, and B-cell tolerance. Animal models appear to be a fruitful "proving ground" of new therapies. The introduction of revised classification criteria for APS should aid in appropriate characterization of, and selection of, patients for clinical trials.

AB - The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains high-intensity warfarin, and, in pregnancy, heparin and aspirin. Exciting developments include the potential role of hydroxychloroquine as a prophylactic drug, stem cell transplantation, and B-cell tolerance. Animal models appear to be a fruitful "proving ground" of new therapies. The introduction of revised classification criteria for APS should aid in appropriate characterization of, and selection of, patients for clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0034207976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034207976&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 256

EP - 261

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 3

ER -